Exalenz launches H pylori breath test in US
This article was originally published in Clinica
Exalenz Bioscience (Modi'in, Israel) has launched its BreathID system in the US for detection of Helicobacter pylori. The point-of-care device, which detects the bacteria in around 10 minutes, analyses changes in carbon 13 and carbon 12 ratios in a patient's breath. H pylori can inhabit the human gastrointestinal tract, causing chronic low-level inflammation that can eventually cause peptic ulcers and stomach cancer. It can be treated with a combination of antibiotics and proton pump inhibitors. The test is the first that Exalenz has launched on its BreathID platform. Meanwhile, the company has also appointed Dennis Boyle vice-president and national manager in the US. Mr Boyle previously worked for Siemens USA.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.